Endoplasmic reticulum (ER) News and Research

RSS

IMPAX sued for patent infringement on generic Ultram ER

IMPAX Laboratories, Inc. today announced Purdue Pharma Products L.P. ("Purdue"), Napp Pharmaceutical Group Ltd. ("Napp"), Biovail Laboratories International, SRL ("Biovail") and Ortho-McNeil, Inc. ("Ortho-McNeil") have filed suit for patent infringement in the United States District Court for the District of Delaware based on the Company's submission of its Abbreviated New Drug Application ("ANDA") for tramadol hydrochloride extended-release tablets (100 mg), generic of Ultram ER, to the Food and Drug Administration.

12 Aug 2008

FDA warns consumers about Baltimore Medicine Shoppe pharmacies

The U.S. Food and Drug Administration is warning consumers who filled prescriptions at The Medicine Shoppe pharmacies located at 8035A Liberty Road and 5900 Reisterstown Road in Baltimore that they may have received drugs that were either expired or suspected counterfeit.

10 Aug 2008

Chronic exposure to estrogen impairs some cognitive functions

University of Illinois researchers report this week that chronic exposure to estradiol, the main estrogen in the body, diminishes some cognitive functions. Rats exposed to a steady dose of estradiol were impaired on tasks involving working memory and response inhibition, the researchers found.

3 Aug 2008

Cell mechanism discovery may lead to new treatments for cystic fibrosis, other inherited diseases

Researchers in Japan and Canada have discovered a key component of the quality control mechanism that operates inside human cells - sometimes too well. The breakthrough has significant implications for the development of new treatments for cystic fibrosis (CF) and some other hereditary diseases, the researchers say. Their results were published July 25 in the journal Science.

29 Jul 2008

Reduced dose anthracycline post-breast cancer surgery has no effect on outcome

Canadian researchers have discovered that there is a low risk of adverse effect from reducing post-op chemo by up to 25%, according to findings published in the online journal ecancermedicalscience.

20 Jul 2008

Does this make me look fat?

The peer groups teenage girls identify with determine how they decide to control their own figure. So reports a new study by Dr. Eleanor Mackey from the Children's National Medical Center in Washington DC, and her colleague Dr. Annette La Greca from the University of Miami.

13 Jul 2008

Black box warning for epilepsy drugs

The U.S. Food and Drug Administration (FDA) is calling for the strongest type of warning to be placed on drugs which are used to treat epilepsy.

8 Jul 2008

Discovery of gene mechanism could lead to new therapeutic strategies to fight metastatic disease

Virginia Commonwealth University and VCU Massey Cancer Center researchers have uncovered how a gene, melanoma differentiation associated gene-7/interleukin-24 (mda-7/IL-24), induces a bystander effect that kills cancer cells not directly receiving mda-7/IL-24 without harming healthy ones, a discovery that could lead to new therapeutic strategies to fight metastatic disease.

1 Jul 2008

Aventix Pharma takes over key patents for innovative screening tool for treatments for cystic fibrosis

The rights to key patents for an innovative screening tool for treatments for cystic fibrosis were transferred today to Swiss biotech company Axentis Pharma AG.

26 Jun 2008

Novel agents found to inhibit growth of estrogen-dependent breast cancer cells

Researchers have discovered a new family of agents that inhibit the growth of estrogen-dependent breast cancer cells. The finding, described at a meeting of the Endocrine Society, has opened an avenue of research into new drugs to combat estrogen-dependent breast cancers.

16 Jun 2008

Anti-estrogen drug therapy reduces risk of invasive breast cancer in older women

New analysis of a drug approved for osteoporosis prevention and treatment has provided definitive evidence that the medication is also effective as a breast cancer preventative for certain cancers.

11 Jun 2008

Reduced incidence of invasive breast cancer with Raloxifene among women at increased coronary risk

Women who took raloxifene were less likely to develop invasive estrogen-receptor (ER) positive breast cancer compared with women who did not, according to data from a randomized controlled trial published online June 10 in the Journal of the National Cancer Institute. The drug did not reduce the risk of non-invasive cancer or invasive ER-negative cancers.

11 Jun 2008

New insight into the genetics of Lou Gehrig's disease

An upcoming paper from Drs. Hidenori Ichijo and Hideki Nishitoh (The University of Tokyo) and colleagues lends new and valuable insight into the genetics of ALS.

1 Jun 2008

Estrogen drives distinct, aggressive prostate cancer

Using a breakthrough technology, researchers led by a Weill Cornell Medical College scientist have pinpointed the hormone estrogen as a key player in about half of all prostate cancers.

28 May 2008

Washington Post series examines childhood obesity

An "epidemic of obesity" is "compromising the lives of millions of American children" and is "expected to add billions of dollars to the U.S. health care bill," the Washington Post reports.

20 May 2008

Aspirin a day cuts risk of common breast cancer

Scientists in the U.S. say an aspirin a day may afford women some protection against the most common type of breast cancer, estrogen receptor or ER-positive breast cancer.

30 Apr 2008

Aspirin and other NSAIDs could lower the risk of breast cancer

Taking aspirin on a daily basis may lower women's risk of a particular type of breast cancer, according to results published in BioMed Central's open access journal Breast Cancer Research.

30 Apr 2008

Breast cancer subtypes are different diseases

There is a biological distinction between breast cancers that depend on hormones and those that do not, according to research published in PLoS Genetics (Friday).

26 Apr 2008

Coffee protects some women against breast cancer

Depending on which variant of a certain gene a woman has, a coffee consumption rate of at least two-three cups a day can either reduce the total risk of developing breast cancer or delay the onset of cancer. This is shown in new research from Lund University and Malmo University in Sweden.

24 Apr 2008

Tredaptive and Janumet recommended for approval in European Union

Food and Drug Administration (FDA) is currently reviewing the combination of extended release (ER) niacin and laropiprant under the trademark Cordaptive (ER niacin/laropiprant). The CHMP recommendation does not apply to regulatory decisions by the FDA and no inferences should be made about pending FDA regulatory actions based on the recommendation of the CHMP.

24 Apr 2008